MP Group – Overview of Biobetters: IV to SC formulation conversion for patient compliance, healthcare savings, and market differentiation

The key highlights of the presentation are: Biobetters are an improved version of a biologic and provide better efficacy, safety and patient compliance while reducing the overall burden on healthcarePotential opportunity for Biosimilars company for marketplace differentiation and evasion of patent dance, and for Innovators to extend product lifecycle and delay biosimilars threatIntravenous (IV) to subcutaneous (SC) conversion is one of the most prudent strategies to address the unmet need of patient compliance while reducing the overall healthcare costsThe current…

Continue Reading
Close Menu